Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug;82(2):327-33.
doi: 10.1016/j.urology.2013.01.078.

Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis

Huei-Ting Tsai  1 , David F Penson, Kepher H Makambi, John H Lynch, Stephen K Van Den Eeden, Arnold L Potosky
Affiliations
Meta-Analysis

Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis

Huei-Ting Tsai et al. Urology. 2013 Aug.

Abstract

Objective: To compare the efficacy of intermittent androgen deprivation therapy (IADT) vs continuous androgen deprivation therapy (CADT) for the treatment of advanced prostate cancer; we performed a meta-analysis of randomized controlled trials (RCTs), assessing the risks of disease progression, all-cause, and disease-specific mortality.

Materials and methods: We conducted a systematic search of several bibliographic systems to identify all RCTs of IADT in men with newly diagnosed metastatic or biochemical only prostate cancer. We abstracted outcome data, study characteristics, and participant demographics. We performed heterogeneity tests and calculated the summarized risk differences (RD) and risk ratios at 95% confidence intervals (CI), using inverse variance methods in random-effects approaches.

Results: We identified 8 RCTs (N = 4664) comparing mortality between IADT and CADT. For all men combined, we observed small but nonsignificant differences in all-cause mortality (RD = 0.02, 95% CI = -0.02, 0.06), disease-specific mortality (RD = 0.04, 95% CI = -0.01, 0.08), and disease progression (RD = -0.03, 95% CI = -0.09, 0.04). Among the prespecified subgroup with histologically confirmed, newly diagnosed metastatic disease, we found no difference in overall survival (RD = 0.00, 95% CI = -0.09, 0.09).

Conclusion: We found no difference in overall survival, but a small increased risk in disease-specific survival for men treated with IADT relative to CADT was observed. IADT could be considered as an alternative to CADT because of better quality of life outcome. Patients should be informed of the possible risks and benefits of both therapies. More research confirming the benefits of IADT vs CADT is needed to inform treatment decisions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Risk difference and risk ratio for comparative efficacy (all-cause and disease-specific mortality, disease progression) and risk of hot flushes between intermittent and continuous androgen deprivation therapy (IADT vs CADT) in 4664 men with advanced prostate cancer enrolled in 8 clinical trials. Studies are listed in an ascending order of median follow-up duration.
See this image and copyright information in PMC

Comment in

  • Editorial comment.
    Filson CP, Hollingsworth JM. Filson CP, et al. Urology. 2013 Aug;82(2):333-4; discussion 334. doi: 10.1016/j.urology.2013.01.079. Urology. 2013. PMID: 23896095 No abstract available.

References

    1. Ismail M, Ferroni M, Gomella LG. Androgen suppression strategies for prostate cancer: is there an ideal approach? Curr Urol Rep. 2011;12:188–196. - PubMed
    1. Youssef E, Tekyi-Mensah S, Hart K, et al. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol. 2003;26:e119–e123. - PubMed
    1. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2009;29:647–653. - PMC - PubMed
    1. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50:2275–2282. - PubMed
    1. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol. 1996;58:139–146. - PubMed

Publication types

MeSH terms

Substances